Sacituzumab govitecan (TROP2 ADC delivering SN-38) posts 35% ORR and 8.0‑mo mPFS in platinum‑resistant ovarian cancer

Sacituzumab govitecan (SG) is a TROP2-directed antibody–drug conjugate that delivers SN-38 (irinotecan’s active metabolite) to TROP2-expressing tumor cells; in this single-institution, open-label Phase II study (NCT06028932), PROC patients received SG 10mg/kg IV on days 1 and 8 q21d. In 20 heavily pretreated patients (median 3 prior lines; range 1–8), investigator-assessed ORR was 35% (7/20) with 0% CR and 40% stable disease; median PFS was 8.0 months (95% CI 3.8–14.8) and median OS was not reached at 9.9 months’ median follow-up—numerically above common single-agent chemo benchmarks in PROC where ORR is often ~10–20% (e.g., PLD ~19.7% and topotecan ~17.0% in recurrent EOC trials) and above the ~3–4‑mo PFS seen with chemo-alone control in AURELIA (mPFS 3.4 mo; adding bevacizumab improved mPFS to 6.7 mo). (pubmed.ncbi.nlm.nih.gov) Safety was consistent with the known SG profile (no new signals): grade 3–4 neutropenia was common (15/20), with other grade 3–4 events including hypokalemia (n=3) and anemia (n=2); low-grade GI toxicity (diarrhea, nausea/vomiting) and alopecia were frequent.